Incidence and Risk of Lung Cancer in Tuberculosis Patients, and Vice Versa: A Literature Review of the Last Decade

Bhowmik, Sutapa; Mohanto, Nayan Chandra; Sarker, Dipanjon; Sorove, Asma Ahsan

doi:https://doi.org/10.1155/2022/1702819

BioMed Research International

On this page

Abstract Background Results Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 1702819 | https://doi.org/10.1155/2022/1702819

Incidence and Risk of Lung Cancer in Tuberculosis Patients, and Vice Versa: A Literature Review of the Last Decade

Sutapa Bhowmik,¹Nayan Chandra Mohanto,²Dipanjon Sarker,¹and Asma Ahsan Sorove¹

Academic Editor: Valeria Cavalcanti Rolla

Received28 Jun 2022

Revised04 Dec 2022

Accepted13 Dec 2022

Published19 Dec 2022

Abstract

Background. The incidence and risk of both lung cancer (LC) and tuberculosis (TB) are increasing rapidly. These two diseases frequently exist together and can influence the incidence and risk of each other. The aim of the current review was to summarize the incidence and risk of LC in TB patients, and vice versa, short out research gap, and contemplate future research perspectives. Methodology. PubMed and Scopus databases, and Google Scholar search engine were searched for epidemiological studies that investigated the incidence and risk of TB and LC, published since January 2011 to April 2022, and written in English. We used the searching keyword “tuberculosis” combined with “lung cancer” and associated medical subject heading (MeSH) to retrieve eligible research articles. We retrieved information’s regarding the diagnosis of TB and LC, confounders, the associations of TB and LC, and incidence and risks of each other. Results. We found higher incidence rate and risks (1.64 to 6 times higher) of LC in TB patients in comparison to non-TB participants. However, the incidence rate and risks of TB in LC patients were comparatively low. Male patients were exhibited higher risks than female. The medical comorbidities, smoking habits, and age can also influence the associations and risks of LC in TB patients or vice versa. Conclusion. Our summarized studies might suggest that existing active TB may increase the incidence and risk of LC. However, large prospective cohort study is warranted to explore the real scenario worldwide.

1. Background

Lung cancer (LC) is the major global health concern and is associated with substantial morbidity and mortality [1–4]. Comparatively, more people die from LC than of colon, breast, and prostate cancers combined worldwide [3]. LC has shown a continuously increasing trend in many countries, and over the time, became the biggest cancer killer of men throughout the world from the rarest form of diseases [5]. Only in 2012, over 1.6 million of people died due to LC. There are two main types of LC including non-small-cell LC (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and small-cell LC [6]. There are several biochemical, genetical and epigenetic, immunological, and epidemiological factors associated with the development of LC [7–9]. The coexistence of some medical conditions and diseases especially tuberculosis (TB) also reported to be associated in the pathogenesis of LC. The incidence and risk for the development of LC have been reported to be increased in patients with both latent TB and active TB [10–13].

Accordingly, TB has killed more humans than any other pathogen, after prolonged coevolution to optimize its pathogenic strategies [14]. An estimated 10 million people were infected with TB worldwide in 2020 irrespective to countries and age groups [15]. It is the top global infectious pandemic after coronavirus disease 2019 (COVID-19) caused by the pathogen Mycobacterium tuberculosis [14]. The latent TB infection (LTBI) describes the condition wherein an individual is infected with bacteria but not currently manifesting active disease [16, 17]. Nearly one-fourth of the world’s population has an LTB infection [15]. Active TB develops in approximately 10% of people with an LTB infection [18, 19]. On the other estimate, people with active TB can infect 5–15 other people through close contact over the course of a year. When people with TB cough, sneeze, or spit, they propel the TB germs into the air and person who inhaled the TB germ-contaminated air is subsequently infected [15]. Active TB is a chronic inflammatory reaction of pulmonary parenchyma that causes irreversible fibrosis and scarring, accompanied by an impaired immune response [20–22]. Chronic TB infections cause the accumulation of genomic changes, and exposure to growth factors can cause multistep cellular transformation, leading to dysplasia and malignant squamous cell carcinoma [23]. Human susceptibility to TB is also associated with polymorphisms of several genes related to innate immunity and the inflammatory response, such as Toll-like receptors, tumor necrosis factors, and inducible nitric oxide; notably, these genes are associated with cancer susceptibility [23–26]. Depending on mechanistic pathways, time required for the development of LC in TB patients is varied, and frequently depends on sociodemographic and lifestyle factors along with some medical comorbidities.

On the contrary, the American Thoracic Society and the Center for Disease Control and Prevention have recognized that LC increases the risk of TB. Patients with LC may exhibit deficiencies in cell-mediated immunity as either a direct effect or an indirect effect related to chemotherapy and consequently developed TB [6, 27]. Some studies also reported the development of TB in LC patients [28–30]. So, a significant level of controversies still exists regarding the association of TB and LC which need to be explored. Accordingly, the coexistence of TB and LC has created great attention to epidemiologist, physician, and clinical researchers since both become deadly. Previously, a few reviews explored the prevalence of LC in TB patients, facts and fiction, and management of coexisting TB and LC [31–34]. However, almost all were systematic reviews and meta-analysis based on single outcome (either TB or LC) that did not explore the worldwide current incidence and risk scenario of TB in LC patients, and vice versa. Therefore, the objectives of the current review were to summarize the study that investigated the incidence and risk of LC in TB patient, and vice versa; to find out potential knowledge gap; and to outline future research perspectives.

2. Methodology

2.1. Database Searching

A systematic search was made in PubMed and Scopus databases, and Google scholar search engine for relevant publications that investigated the associations between TB and LC especially the incidence and risk using the keyword “tuberculosis” AND “lung cancer” and associated medical subject headings (MeSH) to retrieve original research articles of human epidemiological studies. Additional filtering was performed to customize the research based on article type (journal articles), study subjects (human), language (English), and publication year (January 2011 to April 2022). The references of the retrieved research articles were also searched for relevant publications.

2.2. Article Selection

The full-length original research work from all over the world regardless of gender, age groups, and race/ethnicity was included in this review. Inclusion criteria were as follows: (1) epidemiological study that investigated the associations between LC and TB, and evaluated the incidence and risk of LC in TB patients, and vice versa; (2) all ages and/or life stage of disease conditions; (3) outcome either TB or LC; and (4) article must be written in English and published in between January 2011 and April 2022. Information regarding study design, country, number of study subjects, follow-up period of disease development (both endpoints), diagnosis (both LC and TB), covariates or confounders, and incidence and risk of LC in TB patients, and vice versa were retrieved and summarized (Table 1). All the articles addressing case reports, clinical trials, and treatment strategies or intervention were excluded. Finally, a total of 24 articles that fulfill our inclusion criteria were selected and summarized in this review (Table 1). Last two authors of the present study searched and retrieved the existing relevant research articles, and first author cross-checked to minimize the selection bias. We did not select articles based on only positive association rather considered all possible associations (positive, negative, and null).

3. Results

3.1. Study Design, Participants, and Disease Diagnosis

We summarized a total of 24 human epidemiological studies from the last decades including cross-sectional, case-control cohort and retrospective cohort studies that explored the interrelationship between TB and LC incidence, risk, and mortality (Table 1). The study subjects enrolled in these studies were either adults or elderly with the years except one study that recruited years old. The number of total participants was varied among studies, and ranged from 63 to 1607710. Among the 24 studies, LC was the outcome in 16 studies, whereas TB was the outcome in the remaining 8 studies. In the cohort studies, follow-up periods were varied from 1 to 19 years. Most of the studies diagnosed the TB by chest X-ray (CXR) or bacteriological confirmation via microscope, and LC by CXR, CT scan, and PET biopsy and identified based on ICD-9 or 10. All the studies adjusted potential confounders or covariates to strengthen their findings. Major considering covariates were age, sex, smoking, drinking alcohol, and medical comorbidities.

3.2. Incidence and Risk of LC in Patients with TB

All of the cohorts that investigated the risk of LC in TB patients recruited TB participants as case groups and general or non-TB (may exist other disease) individuals as control groups (Table 1). One recent study recruited chronic obstructive pulmonary disease (COPD) and non-COPD participants with and without history of pulmonary TB [35]. The incidence rate ratio (IRR) was varied among studies based on follow-up periods [36–42]. The highest IRR (11-fold higher in TB participants than non-TB participants) was found in a case-control cohort of Taiwanese participants (26.3 vs. 2.41 per 10000 participants) in a total 9-year period of follow-up [41]. On the other hand, the lowest IRR was 1.76 in a total 10-year of follow-up [40]. Accordingly, the IRR highly depends on follow-up duration and was relatively higher in short periods of follow-up than that in long periods [12, 28, 36, 38, 39].

Several studies investigated the relative risk of LC in TB patients. Ho et al. reported approximately 2 times higher risk of secondary LC in TB patients compared to general study participants in Taiwan, whereas other two studies reported 1.64 and 4.37 times higher risk of LC in TB patients [12, 40, 41]. Two separate studies conducted in South Korea in 2020 consequently reported approximately 4 and 6 times higher risk of LC in TB patients than that of control participants, respectively [13, 36]. Other three European studies from Denmark, Netherlands, and Finland were also found 2.24, 1.75, and 2 times higher risk of LC in TB patients, respectively [28, 39, 43]. A few studies found higher mortality and lower survival rate of LC in TB patients compared to non-TB patients [44–46]. Some studies showed sex-specific incidence and risk of LC and stated that men participants had higher risk than that of women participants [13, 36, 47] except one study that reported higher adjusted hazard ratio [6] in women than men [42]. Age-dependent incidence and risk of LC also vary among studies, and most of them showed higher risk in the oldest participants compared to relatively lowest aged participants [36, 37, 42].

Lack of medical facilities and/or treatment and medical comorbidities were also reported to be associated with the increased risk of LC in TB patients [12, 41]. Very recently, one study conducted in South Korea by recruiting both COPD and non-COPD patients with and without PTB showed that COPD patients with baseline history of PTB had higher incidence rate of LC in comparison with COPD patients without PTB [35]. The aHR for LC was significantly higher in COPD patients with PTB in comparison to without PTB, whereas the aHR for LC was not different between PTB and without PTB among non-COPD patients [35].

Most of the studies that investigated the effect of smoking in LC development in TB patients found increased incidence and mortality risk of LC in smoker compared to nonsmoker [13, 37, 47, 48]. However, a recent study reported that never smokers with COPD had higher risk of LC incidence in the participants with PTB compared to those without PTB. In ever smokers (past or current smoker) with COPD, the corresponding risk was null [35].

3.3. Incidence and Risk of TB in Patients with LC

All the existing study that investigated the risk of active TB/LTB in LC patients recruited LC participants as case groups and general or non-LC (may exist other disease) individuals as control groups (Table 1). In 2021, two studies conducted to investigate the incidence and risk of TB in LC patients. Abdelwahab et al. reported that 25% LC patients in Egypt developed LTB with no effect of age, sex, and smoking along with other medical comorbidities [49]. Another study conducted in Canada reported the increased risk of active TB () after 19 years of follow-up [50]. One retrospective study which investigated the incidence and risk of clinically diagnosed TB and bacteriologically confirmed TB (BCTB) in LC patients found the BCTB IRR was 50.35 in comparison with control [51]. One retrospective study in Thailand followed up 18 years and found a cumulative incidence 1.15% for TB in LC patients [52]. Suzuki et al. investigated the cumulated incidence of TB in Japanese LC patients at different follow-up stages and found 0.65%, 1.15%, and 1.38% incidence of TB at 0.5-, 1- and 2-year time periods [53]. Two cohort studies conducted separately in Taiwan evaluated higher TB risk and mortality risk in patients with LC that developed TB in comparison to controls [44, 54]. Wu et al. found higher incidence and risk of TB in LC patients and estimated that the average interval from diagnosis of LC to active TB development time was 748 days [55].

4. Discussion

In this literature review, we summarized the findings of 24 epidemiological studies conducted in the last decade. In brief, the incidence rate and risks of LC were several times higher in TB patients in comparison to general or non-TB populations. On the other hand, the incidence rate and risks of TB in LC patients were relatively low. The participants age, sex, smoking status, and medical comorbidities especially respiratory complications were the major confounder that might increase the risk of LC in TB patients, and vice versa. However, observational studies could not guarantee a causal relationship. For example, surveillance bias, classification bias, and detection bias might have been possible because of the frequent hospital visits of the same participants which might have led to a higher detection rate of TB and/or early-stage LC.

Early diagnosis bias and late treatment strategies of LTB might be another responsible factor for high incidence of TB and LC. Most of the studies of current review diagnosed active and inactive TB by chest X-ray (CXR) that may have led to misclassification of participants as having TB since CXR has high sensitivity but poor specificity for the diagnosis of pulmonary TB [56–58]. However, two studies performed TB diagnosis by QuantiFERON-TB Gold In-Tube tests that is known as the gold standard test [47, 52]. Even pulmonary comorbidities may significantly mask symptoms and delay the diagnosis of LC or may even prevent a full diagnostic evaluation with the proper staging of the disease. Before starting the treatment of TB, the possible disease state of LC also should be diagnosed which can prevent the development of LC.

Similarly, a diagnosis of active TB affects the treatment administered to an LC patient. For example, chemotherapy or surgery may be delayed due to a TB diagnosis or associated medication therapy. Previous study reported that the identification of TB infection interrupted the administration of bortezomib in patients with multiple myeloma, which significantly affected patient outcomes [59]. Moreover, LTBI screening at the time of a diagnosis of a high TB risk LC may enable the prevention of active TB during cancer treatment and empower the appropriate administration of chemotherapy. Cancer patients with decreased cellular immunity face an increased risk of active TB and remain in a prolonged state of immunocompromise. Therefore, LTBI screening and treatment are needed to prevent opportunistic infection and should be performed at the time of LC diagnosis simultaneously.

The increased risk of TB development may be confounded by the associations of smoking and excessive alcohol use, which are also independent risk factors for LC [60, 61]. Therefore, it remains controversial whether TB alone can increase the risk of LC. To clarify the question, most of the studies analysed the association between TB and LC after adjustment of smoking status and alcohol consumption. One study which conducted a stratification analysis by smoking status showed that patients with PTB independently had an increased risk of LC [13]. So, it is noteworthy findings and clear evidence of noncasual effect of TB in LC development. However, contradictory result was addressed in one recent study [35]. They reported that never smoker had higher risk of LC compared to the past or current smoker with the history of PTB. However, the study participants were not general populations rather COPD patients. The findings might be due to the higher percentage of never-smoker COPD patients than that of ever smoker. Another possible reason may be the misdiagnosis of COPD in never-smoker participants. Moreover, they addressed the limitations of their findings by mentioning the necessity for confounder adjustment such as occupational or environmental exposures, which are well-known risk factors for COPD and LC development among never smokers [35, 62–64].

Several medical comorbidities may increase the risk of LC in TB patients, and vice versa. One study demonstrated that both male and female TB patients with asthma and COPD had increased risks of lung SqCC, adenocarcinoma, and SmCC [44]. Recent study also showed that COPD patients with history of PTB have higher risk of LC incidence in comparison to without history of PTB, but in non-COPD patients, the difference was null [35]. The results of the study suggest a potential synergism of PTB and COPD in increasing risk for LC, although PTB is the independent risk factors for both COPD and LC [35, 56]. However, the reason why PTB patients without COPD did not develop LC limits their discussion. Furthermore, like COPD, the presence of several baseline chronic inflammatory diseases especially HIV and AIDS may increase the incidence of LC in TB patients, an issue that was not addressed [56]. On the other hand, previous studies stated that patients with other cancer including oesophageal cancer, pancreatic cancer, hematologic malignancy, and head and neck cancer faced a particularly high risk of developing TB [13, 51]. Even histological types of LC, including SmCC and sarcoma, were strongly associated with TB [13]. So, it would be highly appreciating to investigate the incidence and risk of all possible cancer with their histologic types in TB patients in the future. Determining risk factors for specific types of LC can help physicians gain a detailed understanding of the etiology of LC and therefore identify the high-risk population for screening. On the contrary, patients with chronic kidney disease may receive long-term steroid therapy and chemotherapy, which may account for the increased risk of TB [65]. Thus, a study adjusting all possible medical comorbidities is highly expected as few studies did it which strengthens the evidence [12, 41, 55].

The LC incidence rate and risk were found to be higher in men than that of women especially in Asian countries [13, 36, 47]. The reason behind this finding might be explained by the smoking status and tendency. Smoking tendency and frequency in men are higher in compared to women in Asian country; for example, the prevalence of smoking is almost 10-fold higher in Taiwanese men than that in women [66]. Also, male populations were frequently exposed to environmental pollutants than that of their women partners in which some pollutants are strongly associated with respiratory diseases that might regulate TB pathogenesis.

4.1. Knowledge Gaps

One of the limitations of the outlined studies is the ethnic background. Majority of the studies were conducted in Asian countries limiting the generalizability of outcomes in worldwide perspectives. Although the number of study participants was significantly high, the overall low number of active TB or LC in comparison to control group might result in limited statistical power of analyses. Some studies recruited self-reported TB patients that causes potential misclassification because not all subjects may remember their respiratory TB, or they may be unaware that they have had TB in the past. TB and LC have been confused and misdiagnosed for years due to similar clinical symptoms of both diseases. Thus, TB might imitate or mask LC. Some studies excluded laboratory results, such as sputum culture, exercise capacity, lifestyle data, nutrition supplements, and family history of systemic disease and specific chemotherapeutic regimens, and the health insurance data utilized did not include the histological stage and severity of primary cancer that may affect the metastatic ability. The possibility of sampling bias in the diagnosis of TB could not be excluded since some studies did not consider comorbidities such as diabetes, malnutrition, asthma, COPD or other lung diseases, HIV infection, renal insufficiency, and immunosuppressant therapies. Some studies did not consider lifestyle-related factors such as obesity, physical inactivity, diet and habits, and family history, which are closely associated with LC [67, 68]. Retrospective studies are at risk of selection bias (cases lost to follow-up) and measurement bias (data obtained from medical records) that may have resulted in a bias in the results too. Few studies had no appropriate control group to compare the incidence and risk of TB or LC and did not find evidence for synergism. Another limitation is unavailable data on the prognostic factor WHO performance status of LC cases. As cancer patients usually receive greater medical attention in terms of frequent examinations, this might contribute to a higher rate of notified TB cases among LC patients. There is a possibility of ascertainment bias through which patients with an index diagnosis are more likely to have another disease diagnosed compared with patients without the index diagnosis.

4.2. Future Perspectives

In our summarized studies, some enrolled TB patients are from only one hospital. Therefore, recruitment of baseline patients (TB or LC) national wide or from multiple hospital and clinics will be appreciated. In addition, the selection of control group or general populations should be well defined to avoid the bias. So, in order to evaluate the risk factors of concomitant TB and LC, multicenter and prospective studies are required in the future. Furthermore, the prevalence of TB and LC treatments varies according to the country and the era. Hence, these factors should be considered when adopting or comparing results with those of other countries or previously reported data. Inclusion of the information on the diagnosis of TB and LC, and histologic types of LC, could have strengthened the analyses. The follow-up trajectories of the LC in TB patients or vice versa for several years should have neem conducted to evaluate minimum time required for the transformation of TB to LC or vice versa. Since the risk of LC in TB patients or vice versa depends to a great extent on TB epidemiological situation in certain geographic region, the study should be carefully generalized in countries with low TB or LC incidence. The possible noncausal factors, for example, common genetic or environmental precursor and infectious and noncommunicable diseases which may lead independently to TB and LC, should be considered at baseline and through the follow-up periods. Path analysis might shed light among the relationship of sociodemographic and lifestyle factors, medical comorbidities, environmental chemicals with concomitant TB in LC development, and/or vice versa in the future. Furthermore, investigation of synergistic relationships of TB and potential medical comorbidities especially COPD, asthma or other lung diseases, HIV and other microbes in the development of LC is highly recommended in large-scale cohort. The mechanistic overview of how TB patients develop LC in patients with these comorbidities should also be addressed in the future. Finally, follow-up screening of TB and LC should continuously assess and ensure the modern diagnosis and treatment strategies to prevent secondary form of diseases and to manage long-term respiratory complications due to TB survival [69–71].

5. Conclusion

Our summarized studies explicitly suggest that existing TB can increase the incidence rate and risk of LC, and vice versa. The patients’ age, sex and medical comorbidities might influence the relationships. Large prospective cohort study is warranted exploring the deep scenario in the future.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

All authors have declared no conflict of interest.

Authors’ Contributions

SB is responsible for the investigation, data curation, and writing-original draft (in part). NCM is responsible for writing-original draft, conceptualization, supervision, and writing-review editing. DS and AAS are responsible for the investigation, data curation, and writing-review and editing. All authors read the manuscript and approved the current version. Dipanjon Sarker and Asma Ahsan Sorove contributed equally to this work.

References

J. A. Barta, C. A. Powell, and J. P. Wisnivesky, “Global epidemiology of lung cancer,” Annals of Global Health, vol. 85, no. 1, 2019.
View at: Google Scholar
J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
View at: Publisher Site | Google Scholar
H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
View at: Publisher Site | Google Scholar
M. C. S. Wong, X. Q. Lao, K. F. Ho, W. B. Goggins, and S. L. A. Tse, “Incidence and mortality of lung cancer: global trends and association with socioeconomic status,” Scientific Reports, vol. 7, no. 1, p. 14300, 2017.
View at: Publisher Site | Google Scholar
J. Didkowska, U. Wojciechowska, M. Mańczuk, and J. Łobaszewski, “Lung cancer epidemiology: contemporary and future challenges worldwide,” Annals of translational medicine, vol. 4, no. 8, p. 150, 2016.
View at: Publisher Site | Google Scholar
S. Saab, H. Zalzale, Z. Rahal, Y. Khalifeh, A. Sinjab, and H. Kadara, “Insights into lung cancer immune-based biology, Prevention, and Treatment,” Frontiers in immunology, vol. 11, p. 159, 2020.
View at: Publisher Site | Google Scholar
I. Harkati, M. K. Hilali, N. Oumghar, M. Khouchani, and M. Loukid, “Lifestyle and sociodemographic and economic characteristics of patients with lung cancer in Morocco,” Canadian Respiratory Journal, vol. 2020, Article ID 8031541, 8 pages, 2020.
View at: Publisher Site | Google Scholar
A. C. MacKinnon, J. Kopatz, and T. Sethi, “The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies,” British Medical Bulletin, vol. 95, no. 1, pp. 47–61, 2010.
View at: Publisher Site | Google Scholar
H. J. Yoon and G. Tourassi, “Investigating the association between sociodemographic factors and lung cancer risk using cyber informatics,” in 2016 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI), pp. 557–560, Las Vegas, NV, USA, 2016.
View at: Google Scholar
H. Abdeahad, M. Salehi, A. Yaghoubi, A. H. Aalami, F. Aalami, and S. Soleimanpour, “Previous pulmonary tuberculosis enhances the risk of lung cancer: systematic reviews and meta-analysis,” Infectious Diseases, vol. 54, no. 4, pp. 255–268, 2022.
View at: Publisher Site | Google Scholar
E. A. Engels, M. Shen, R. S. Chapman et al., “Tuberculosis and subsequent risk of lung cancer in Xuanwei, China,” International journal of cancer, vol. 124, no. 5, pp. 1183–1187, 2009.
View at: Publisher Site | Google Scholar
L. J. Ho, H. Y. Yang, C. H. Chung et al., “Increased risk of secondary lung cancer in patients with tuberculosis: a nationwide, population-based cohort study,” PLoS One, vol. 16, no. 5, article e0250531, 2021.
View at: Publisher Site | Google Scholar
C. M. Oh, Y. H. Roh, D. Lim et al., “Pulmonary tuberculosis is associated with elevated risk of lung cancer in Korea: the nationwide cohort study,” Journal of Cancer, vol. 11, no. 7, pp. 1899–1906, 2020.
View at: Publisher Site | Google Scholar
P. Elkington, M. E. Polak, M. T. Reichmann, and A. Leslie, “Understanding the tuberculosis granuloma: the matrix revolutions,” Trends in Molecular Medicine, vol. 28, no. 2, pp. 143–154, 2022.
View at: Publisher Site | Google Scholar
WHO, Tuberculosis, https://www.who.int/health-topics/tuberculosis#tab=tab_1.
A. W. Steele, S. Eisert, A. Davidson et al., “Using computerized clinical decision support for latent tuberculosis infection screening,” American Journal of Preventive Medicine, vol. 28, no. 3, pp. 281–284, 2005.
View at: Publisher Site | Google Scholar
Y. J. Wong, N. M. Noordin, S. Keshavjee, and S. W. H. Lee, “Impact of latent tuberculosis infection on health and wellbeing: a systematic review and meta-analysis,” European respiratory review, vol. 30, no. 159, p. 200260, 2021.
View at: Publisher Site | Google Scholar
C. Carranza, S. Pedraza-Sanchez, E. de Oyarzabal-Mendez, and M. Torres, “Diagnosis for latent tuberculosis infection: new alternatives,” Frontiers in Immunology, vol. 11, 2020.
View at: Publisher Site | Google Scholar
L. Muñoz, H. R. Stagg, and I. Abubakar, “Diagnosis and management of latent tuberculosis infection,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 11, article a017830, 2015.
View at: Publisher Site | Google Scholar
K. Dheda, H. Booth, J. F. Huggett, M. A. Johnson, A. Zumla, and G. A. Rook, “Lung remodeling in pulmonary tuberculosis,” The Journal of Infectious Diseases, vol. 192, no. 7, pp. 1201–1209, 2005.
View at: Publisher Site | Google Scholar
S. Ravimohan, H. Kornfeld, D. Weissman, and G. P. Bisson, “Tuberculosis and lung damage: from epidemiology to pathophysiology,” European respiratory review, vol. 27, no. 147, p. 170077, 2018.
View at: Publisher Site | Google Scholar
C. Stek, B. Allwood, N. F. Walker, R. J. Wilkinson, L. Lynen, and G. Meintjes, “The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy,” Frontiers in Microbiology, vol. 9, pp. 2603–2603, 2018.
View at: Publisher Site | Google Scholar
A. Nalbandian, B. S. Yan, A. Pichugin, R. T. Bronson, and I. Kramnik, “Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control,” Oncogene, vol. 28, no. 17, pp. 1928–1938, 2009.
View at: Publisher Site | Google Scholar
A. K. Azad, W. Sadee, and L. S. Schlesinger, “Innate immune gene polymorphisms in tuberculosis,” Infection and Immunity, vol. 80, no. 10, pp. 3343–3359, 2012.
View at: Publisher Site | Google Scholar
T. Qidwai and F. Khan, “Tumour necrosis factor gene polymorphism and disease prevalence,” Scandinavian Journal of Immunology, vol. 74, no. 6, pp. 522–547, 2011.
View at: Publisher Site | Google Scholar
S. Zhang, X. B. Wang, Y. D. Han, C. Wang, Y. Zhou, and F. Zheng, “Certain polymorphisms in SP110 gene confer susceptibility to tuberculosis: a comprehensive review and updated meta-analysis,” Yonsei Medical Journal, vol. 58, no. 1, pp. 165–173, 2017.
View at: Publisher Site | Google Scholar
Y. H. Kim, K. Goto, K. Yoh et al., “Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy,” Cancer, vol. 113, no. 9, pp. 2518–2523, 2008.
View at: Publisher Site | Google Scholar
M. S. Shiels, D. Albanes, J. Virtamo, and E. A. Engels, “Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study,” Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol. 20, no. 4, pp. 672–678, 2011.
View at: Publisher Site | Google Scholar
V. Cukic, “The association between lung carcinoma and tuberculosis,” Medical archives, vol. 71, no. 3, pp. 212–214, 2017.
View at: Publisher Site | Google Scholar
J. Cabrera-Sanchez, V. Cuba, V. Vega, P. Van der Stuyft, and L. Otero, “Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis,” European respiratory review, vol. 31, no. 165, p. 220025, 2022.
View at: Publisher Site | Google Scholar
D. R. Brenner, J. R. McLaughlin, and R. J. Hung, “Previous lung diseases and lung cancer risk: a systematic review and meta-analysis,” PLoS One, vol. 6, no. 3, article e17479, 2011.
View at: Publisher Site | Google Scholar
A. Christopoulos, M. W. Saif, E. G. Sarris, and K. N. Syrigos, “Epidemiology of active tuberculosis in lung cancer patients: a systematic review,” The Clinical Respiratory Journal, vol. 8, no. 4, pp. 375–381, 2014.
View at: Publisher Site | Google Scholar
J. C. Ho and C. C. Leung, “Management of co-existent tuberculosis and lung cancer,” Lung cancer, vol. 122, pp. 83–87, 2018.
View at: Publisher Site | Google Scholar
C. Molina-Romero, O. Arrieta, and R. Hernández-Pando, “Tuberculosis and lung cancer,” Salud publica de Mexico, vol. 61, no. 3, may-jun, pp. 286–291, 2019.
View at: Publisher Site | Google Scholar
H. Y. Park, D. Kang, S. H. Shin et al., “Pulmonary tuberculosis and the incidence of lung cancer among patients with chronic obstructive pulmonary disease,” Annals of the American Thoracic Society, vol. 19, no. 4, pp. 640–648, 2022.
View at: Publisher Site | Google Scholar
S. J. An, Y. J. Kim, S. S. Han, and J. Heo, “Effects of age on the association between pulmonary tuberculosis and lung cancer in a south Korean cohort,” Journal of Thoracic Disease, vol. 12, no. 3, pp. 375–382, 2020.
View at: Publisher Site | Google Scholar
R. Everatt, I. Kuzmickiene, E. Davidaviciene, and S. Cicenas, “Incidence of lung cancer among patients with tuberculosis: a nationwide cohort study in Lithuania,” The international journal of tuberculosis and lung disease, vol. 20, no. 6, pp. 757–763, 2016.
View at: Publisher Site | Google Scholar
S. C. Kuo, Y. W. Hu, C. J. Liu et al., “Association between tuberculosis infections and non-pulmonary malignancies: a nationwide population-based study,” British Journal of Cancer, vol. 109, no. 1, pp. 229–234, 2013.
View at: Publisher Site | Google Scholar
D. F. Simonsen, D. K. Farkas, M. Søgaard, C. R. Horsburgh, H. T. Sørensen, and R. W. Thomsen, “Tuberculosis and risk of cancer: a Danish nationwide cohort study,” The international journal of tuberculosis and lung disease, vol. 18, no. 10, pp. 1211–1219, 2014.
View at: Publisher Site | Google Scholar
C. Y. Wu, H. Y. Hu, C. Y. Pu et al., “Pulmonary tuberculosis increases the risk of lung cancer,” Cancer, vol. 117, no. 3, pp. 618–624, 2011.
View at: Publisher Site | Google Scholar
Y. H. Yu, C. C. Liao, W. H. Hsu et al., “Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 32–37, 2011.
View at: Publisher Site | Google Scholar
J. Y. Huang, Z. H. Jian, O. N. Nfor et al., “The effects of pulmonary diseases on histologic types of lung cancer in both sexes: a population-based study in Taiwan,” BMC Cancer, vol. 15, no. 1, p. 834, 2015.
View at: Publisher Site | Google Scholar
M. E. Heuvers, J. G. Aerts, J. P. Hegmans et al., “History of tuberculosis as an independent prognostic factor for lung cancer survival,” Lung cancer, vol. 76, no. 3, pp. 452–456, 2012.
View at: Publisher Site | Google Scholar
J. Y. Huang, Z. H. Jian, O. Ndi Nfor et al., “The impact of coexisting asthma, chronic obstructive pulmonary disease and tuberculosis on survival in patients with lung squamous cell carcinoma,” PloS one, vol. 10, no. 7, article e0133367, 2015.
View at: Publisher Site | Google Scholar
C. C. Leung, L. Hui, R. S. Lee et al., “Tuberculosis is associated with increased lung cancer mortality,” The international journal of tuberculosis and lung disease, vol. 17, no. 5, pp. 687–692, 2013.
View at: Publisher Site | Google Scholar
Y. Zhou, Z. Cui, X. Zhou et al., “The presence of old pulmonary tuberculosis is an independent prognostic factor for squamous cell lung cancer survival,” Journal of Cardiothoracic Surgery, vol. 8, no. 1, p. 123, 2013.
View at: Publisher Site | Google Scholar
S. Hong, Y. Mok, C. Jeon, S. H. Jee, and J. M. Samet, “Tuberculosis, smoking and risk for lung cancer incidence and mortality,” International Journal of Cancer, vol. 139, no. 11, pp. 2447–2455, 2016.
View at: Publisher Site | Google Scholar
J. M. Bae, Z. M. Li, M. H. Shin, D. H. Kim, M. S. Lee, and Y. O. Ahn, “Pulmonary tuberculosis and lung cancer risk in current smokers: the Seoul male cancer cohort study,” Journal of Korean Medical Science, vol. 28, no. 6, pp. 896–900, 2013.
View at: Publisher Site | Google Scholar
H. W. Abdelwahab, M. O. Elmaria, D. A. Abdelghany et al., “Screening of latent TB infection in patients with recently diagnosed bronchogenic carcinoma,” Asian Cardiovascular & Thoracic Annals, vol. 29, no. 3, pp. 208–213, 2021.
View at: Publisher Site | Google Scholar
D. S. Kumar, L. A. Ronald, K. Romanowski et al., “Risk of active tuberculosis in migrants diagnosed with cancer: a retrospective cohort study in British Columbia, Canada,” BMJ Open, vol. 11, no. 3, article e037827, 2021.
View at: Publisher Site | Google Scholar
J. Cheon, C. Kim, E. J. Park et al., “Active tuberculosis risk associated with malignancies: an 18-year retrospective cohort study in Korea,” Journal of Thoracic Disease, vol. 12, no. 9, pp. 4950–4959, 2020.
View at: Publisher Site | Google Scholar
S. Nanthanangkul, S. Promthet, K. Suwanrungruang, C. Santong, and P. Vatanasapt, “Incidence of and risk factors for tuberculosis among cancer patients in endemic area: a regional cohort study,” Asian Pacific journal of cancer prevention: APJCP, vol. 21, no. 9, pp. 2715–2721, 2020.
View at: Publisher Site | Google Scholar
Y. Suzuki, S. Imokawa, J. Sato, T. Uto, and T. Suda, “Cumulative incidence of tuberculosis in lung cancer patients in Japan: a 6-year observational study,” Respiratory Investigation, vol. 54, no. 3, pp. 179–183, 2016.
View at: Publisher Site | Google Scholar
W. C. Fan, W. Y. Ting, M. C. Lee et al., “Latent TB infection in newly diagnosed lung cancer patients - a multicenter prospective observational study,” Lung cancer, vol. 85, no. 3, pp. 472–478, 2014.
View at: Publisher Site | Google Scholar
C. Y. Wu, H. Y. Hu, C. Y. Pu et al., “Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study,” The international journal of tuberculosis and lung disease, vol. 15, no. 1, pp. 125–130, 2011.
View at: Google Scholar
J. S. Zifodya and K. Crothers, “Tuberculosis, chronic obstructive lung disease, and lung cancer: the holey upper lobe trinity?” Annals of the American Thoracic Society, vol. 19, no. 4, pp. 540–542, 2022.
View at: Publisher Site | Google Scholar
J. L. Hart and S. P. Taylor, “Family presence for critically ill patients during a pandemic,” Chest, vol. 160, no. 2, pp. 549–557, 2021.
View at: Publisher Site | Google Scholar
J. L. Hart, A. E. Turnbull, I. M. Oppenheim, and K. R. Courtright, “Family-centered care during the COVID-19 era,” Journal of Pain and Symptom Management, vol. 60, no. 2, pp. e93–e97, 2020.
View at: Publisher Site | Google Scholar
J. S. Ahn, S. Y. Rew, D. H. Yang et al., “Poor prognostic significance of mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma,” Blood research, vol. 48, no. 1, pp. 35–39, 2013.
View at: Publisher Site | Google Scholar
R. Alavi-Naini, B. Sharifi-Mood, and M. Metanat, “Association between tuberculosis and smoking,” International journal of high risk behaviors & addiction, vol. 1, no. 2, pp. 71–74, 2012.
View at: Publisher Site | Google Scholar
T. Volkmann, P. K. Moonan, R. Miramontes, and J. E. Oeltmann, “Tuberculosis and excess alcohol use in the United States, 1997-2012,” The international journal of tuberculosis and lung disease, vol. 19, no. 1, pp. 111–119, 2015.
View at: Publisher Site | Google Scholar
S. S. Salvi and P. J. Barnes, “Chronic obstructive pulmonary disease in non-smokers,” The Lancet, vol. 374, no. 9691, pp. 733–743, 2009.
View at: Publisher Site | Google Scholar
B. Lamprecht, M. A. McBurnie, W. M. Vollmer et al., “COPD in never smokers: results from the population-based burden of obstructive lung disease study,” Chest, vol. 139, no. 4, pp. 752–763, 2011.
View at: Publisher Site | Google Scholar
L. Mu, L. Liu, R. Niu et al., “Indoor air pollution and risk of lung cancer among Chinese female non-smokers,” Cancer causes & control: CCC, vol. 24, no. 3, pp. 439–450, 2013.
View at: Publisher Site | Google Scholar
C. H. Li, H. J. Chen, W. C. Chen et al., “The risk of tuberculosis infection in non-dialysis chronic kidney disease patients,” Frontiers in Medicine, vol. 8, article 715010, 2021.
View at: Publisher Site | Google Scholar
Y. W. Tsai, T. I. Tsai, C. L. Yang, and K. N. Kuo, “Gender differences in smoking behaviors in an Asian population,” Journal of Women's Health, vol. 17, no. 6, pp. 971–978, 2008.
View at: Publisher Site | Google Scholar
Y. X. Lei, W. C. Cai, Y. Z. Chen, and Y. X. Du, “Some lifestyle factors in human lung cancer: a case-control study of 792 lung cancer cases,” Lung cancer, vol. 14, Supplement 1, pp. S121–S136, 1996.
View at: Publisher Site | Google Scholar
Y. X. Du, Q. Cha, X. W. Chen et al., “An epidemiological study of risk factors for lung cancer in Guangzhou, China,” Lung cancer, vol. 14, Supplement 1, pp. S9–37, 1996.
View at: Publisher Site | Google Scholar
M. Pai, M. P. Nicol, and C. C. Boehme, “Tuberculosis diagnostics: state of the art and future directions,” Tuberculosis and the Tubercle Bacillus, vol. 4, no. 5, pp. 361–378, 2016.
View at: Google Scholar
J. S. Zifodya, J. S. Kreniske, I. Schiller et al., “Xpert ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis,” The Cochrane database of systematic reviews, no. 2, article Cd009593, 2021.
View at: Publisher Site | Google Scholar
S. E. Dorman, P. Nahid, E. V. Kurbatova et al., “Four-month rifapentine regimens with or without moxifloxacin for tuberculosis,” The New England Journal of Medicine, vol. 384, no. 18, pp. 1705–1718, 2021.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Sutapa Bhowmik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

747

Downloads

648

Citations